Trial Profile
A global multicentre observational study in rheumatoid arthritis patients who are nonresponders or intolerant to a single tumour necrosis factor (TNF) inhibitor.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Roche
- 26 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
- 02 Dec 2009 New trial record